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Abstract Dinucleotide polyphosphates (ApnA) have emerged as
signaling molecules in rapidly dividing cells. The presence and
role of Ap5A in the heart remain unknown. Here, we report that
the myocardium contains abundant amounts of diadenosine 5P,5Q-
P1,P5-pentaphosphate (Ap5A), a member of the ApnA family.
Ischemia induced 10-fold decrease in the myocardial concentra-
tion of Ap5A. A target of Ap5A action was identified to be the
cardiac ATP-sensitive K+ (KATP) channel, a metabolism-
sensitive ion conductance activated in ischemia. At levels found
in hearts prior to ischemia, Ap5A maintained a low probability of
KATP channel opening, but at levels found in harts following
ischemia, Ap5A allowed a high probability of KATP channel
opening. Taken together, the present data suggest that Ap5A
harbors the properties of a signaling molecule involved in the
cardiac response to metabolic stress.
z 1998 Federation of European Biochemical Societies.
Key words: Diadenosine polyphosphate;
Diadenosine pentaphosphate; KATP channel; Ischemia; Heart
1. Introduction
Diadenosine polyphosphates (ApnA) are dinucleotides
composed of two adenosine moieties linked through ribose
5P-carbons to a phosphate group chain of di¡erent length
(n = 2^6). Although biosynthesis of such molecules has been
postulated four decades ago [1], the presence and role of
ApnA in mammalian tissue still remains controversial [2^4].
More recently, intracellular ApnA have emerged as putative
signaling molecules implicated in the maintenance of vital
cellular functions [2,3,5^9]. In prokaryotic cells, changes in
the concentration of cytosolic ApnA have been reported dur-
ing oxidative stress and associated with binding to, and inhib-
ition of oxidative stress-related proteins [10,11]. In eukaryotes,
the role of ApnA in the response to oxidative stress remains
unknown.
Here, we report that a member of the ApnA family, dia-
denosine 5P,5Q-P1,P5-pentaphosphate (Ap5A), is present in the
heart, senses the metabolic state of the myocardium, and tar-
gets a metabolism-sensing ion conductance. This provides the
¢rst evidence for a role of a member of the ApnA family in
the cardiac response to oxidative stress.
2. Materials and methods
2.1. Measurement of Ap5A in heart muscle
Cardiac ventricles, obtained from adult guinea-pigs (350^450 g;
anesthetized with 40 mg/kg sodium pentobarbital, i.p.), were frozen
at 370‡C. In certain experiments, hearts were ¢rst made globally
ischemic by shutting-o¡ coronary perfusion for 10 min [12]. Tissue
specimens (1 g) were pulverized under liquid nitrogen, the powder
added to 2 ml ice-cold perchloric acid (0.7 M), homogenized and
the mixture centrifuged (3000Ug, 15 min, 4‡C). The supernatant
(2 ml) was removed and mixed with 4 ml freon (1.1.2-trichlorotri£uo-
roethan and tri-n-octylamine in a ratio of 7.81:2.19), and this mixture
centrifuged (3000Ug, 10 min, 4‡C). The obtained supernatant was
adjusted to pH 7.5 with 5 M KOH, and Ap5A measured by high
performance liquid chromatography (HPLC), as previously described
[13,14]. HPLC analysis was performed, at room temperature, using a
C18 reversed phase column (Phenomenex, 250U4.6 mm, 5 Wm par-
ticles), protected by a Guard Pack module. The chromatographic
system consisted of the LKB delivery system (2152 LC Controler),
LKB injector (2157 Autosampler), linear UV detector (UVIS 204)
and a Hitachi module integrator (D-2500). The injected volume was
100 Wl. The mobile phase was composed of 10 mM K2HPO4, 2 mM
tetrabutylammonium and 17% acetonitrile, at pH 7.5. Detection was
monitored at 260 nm. A linear correlation between injected doses (0^
12 nmol) of synthetic Ap5A and corresponding peak areas on chro-
matograms was obtained (r = 0.999995). The concentrations of Ap5A
in ventricular tissue extract were calculated based upon peak areas of
Ap5A standards injected before each experiment.
2.2. Single channel recordings
Ventricular cardiomyocytes were dissociated from pentobarbital-
anesthetized guinea-pigs using an established enzymatic procedure
[15,16]. In brief, hearts were retrogradely perfused (at 37‡C) with
medium 199 for 2^3 min, followed by Ca2-EGTA-bu¡ered low-
Ca2 medium (pCa = 7) for 80 s, and ¢nally low-Ca2 medium con-
taining pronase E (8 mg per 100 ml), proteinase K (1.7 mg per 100
ml), bovine albumin (0.1 g per 100 ml, fraction V) and 200 WM CaCl2.
Ventricles were cut into small fragments (6^10 mm3) in the low-Ca2
medium enriched with 200 WM CaCl2. Single cells were isolated by
stirring the tissue (at 37‡C) in a solution containing pronase E and
proteinase K supplemented with collagenase (5 mg per 10 ml). After
10 min, the ¢rst aliquot was removed, ¢ltered through a nylon sieve,
centrifuged for 60 s (at 300^400 rpm), and washed twice. Remaining
tissue fragments were re-exposed to collagenase, and isolation contin-
ued for 2^3 such cycles. Isolated cardiomyocytes were stored in low-
Ca2 medium with 200 WM CaCl2. Rod-shaped cardiomyocytes with
clear striations and smooth surface were used for electrophysiological
recordings. Cells were superfused with (in mM): KCl 140, MgCl2 1,
EGTA 5, HEPES-KOH 5 (pH 7.4). Fire-polished pipettes, coated
with Sylgard (resistance 5^7 m6), were ¢lled with (in mM): KCl
140, CaCl2 1, MgCl2 1, HEPES-KOH 5 (pH 7.3). The gigaohm seal
patch-clamp technique was applied in the inside-out con¢guration
[17,18]. Recordings were made at room temperature (22‡C), using a
patch-clamp ampli¢er (Axopatch-1C). Single channel activity was
monitored on-line on a high-gain digital storage oscilloscope (VC-
6025; Hitachi) and stored on tape with the aid of a PCM converter
system (VR-10, Instrutech). Data were reproduced, low-pass ¢ltered
at 4 kHz (33 dB) by a Bessel ¢lter (Frequency Devices 902), sampled
at 80 Ws rate, and further analyzed using the ‘BioQuest’ software
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Fig. 1. Identi¢cation of diadenosine 5P,5Q-P1,P5-pentaphosphate (Ap5A) in the heart by HPLC. A and B: Elution pro¢les of synthetic Ap5A (5
nmoles, Sigma) (A) or ventricular tissue extract (100 Wl) from normoxic heart (B). A1 and B1: Elution pro¢les of fractions recovered from
peaks of interest in A (1/200; A1) and B (1/7; B1), lyophilized and rechromatographed. A2 and B2: Elution pro¢les of the fraction recovered
from peaks of interest in A (1/200; A1) and B (1/7; B1), lyophilized, incubated with phosphodiesterase I (Sigma, EC 3.1.4.1. at 3 mU/ml dur-
ing 10 min; 37‡C) and rechromatographed. Each peak of interest is labeled by a vertical arrow, and the retention time (in min) and peak area
(arbitrary units) indicated. Note similar elution pro¢les for synthetic Ap5A and the peak of interest in ventricular tissue extract under various
experimental conditions.
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[19,20]. The threshold for judging the open state was set at half of the
single channel amplitude. Channel activity, assayed by digitizing seg-
ments of current recordings and forming histograms of base line and
open level data points, were expressed as NPo (N, number of channels
in the patch; Po, probability of each channel to be open).
2.3. Statistics
Results are expressed as mean þ standard error of the mean; n
refers to the number of animals. Signi¢cant di¡erences between two
means were determined with the Student’s t-test (P6 0.05 was con-
sidered signi¢cant).
3. Results and discussion
Synthetic Ap5A, subjected to ion-pair chromatography,
had a retention time of 67.99 þ 2.27 min (n = 8; Fig. 1A).
This retention time was signi¢cantly di¡erent from that of
other synthetic nucleotides, i.e. NAD (3.24 þ 0.03 min,
n = 6), AMP (4.95 þ 0.16 min, n = 6), diadenosine triphosphate
(10.01 þ 0.29 min, n = 6), ADP (10.02 þ 0.29 min, n = 6), FAD
(12.51 þ 0.35 min, n = 6), ATP (21.65 þ 0.60 min, n = 6), diade-
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Fig. 2. Ischemia decreased the levels of Ap5A in cardiac tissue. A: Elution pro¢le of synthetic Ap5A (4 nmol) in the presence of a cocktail of
synthetic nucleotides (upper panel). Elution pro¢le of ventricular tissue extract (100 Wl) from normoxic (middle panel) and 10-min ischemic
(lower panel) hearts. The peak corresponding to Ap5A is indicated by an arrow. For each peak of interest the retention time (in min) and
peak area (arbitrary units) are indicated. B: Average values of the estimated levels of Ap5A in normoxic (open bar; n = 6) and ischemic
(hatched bar; n = 4) hearts. Vertical bars represent mean þ S.E.M. (*P6 0.001).
Fig. 3. Ap5A regulates the opening of cardiac KATP channels. A: Concentration-response curve of Ap5A versus KATP channel activity. Data
points represent mean þ S.E.M. (n = 3^6). Results are expressed as percentage of maximal channel activity determined in the absence of a ligand.
B: E¡ect of normoxic and ischemic levels of Ap5A on KATP channel opening. Vertical bars represent mean þ S.E.M. (n = 4^6). *P6 0.001 (un-
paired t-test). Results are expressed as percentage of complete channel inhibition (100% when NPo = 0). C: Upper traces: continuous recording
of KATP channel activity in the presence of normoxic (left panel) and ischemic (right panel) levels of Ap5A. Lower traces: corresponding NPo
values calculated over 0.25-s long intervals. Dotted line represents the zero current level. Holding potential : 360 mV.
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nosine tetraphosphate (28.07 þ 0.92 min, n = 6) and diadeno-
sine hexaphosphate (140.56 min, n = 1). Thus, the used exper-
imental procedure allowed separation of Ap5A from other
nucleotides.
In ventricular tissue extracts, subjected to the same proce-
dure, a peak occurred at 67.4 þ 2.0 min (n = 10; Fig. 1B), a
retention time not signi¢cantly di¡erent from that recorded
for synthetic Ap5A (Ps 0.05). This peak was isolated from
other peaks (13.7 þ 4.4 min from the closest peak; n = 10) on
the chromatogram of ventricular tissue extracts (Fig. 1B). On
rechromatography, the puri¢ed ventricular fraction, corre-
sponding to the peak of interest, appeared with a retention
time (Fig. 1B1) that was also indistinguishable from rechro-
matographed, synthetic, Ap5A (Fig. 1A1). The puri¢ed ven-
tricular fraction and synthetic Ap5A were both degraded by
phosphodiesterase I (EC 3.1.4.1. at 3 mU/ml for 10 min;
37‡C; Fig. 1A2 and B2), an enzyme known to cleave ApnA
[12,13], but not by alkaline phosphatase (EC 3.1.3.1. at 1 mU/
ml for 1 h; 37‡C; data not shown), an enzyme to which ApnA
are resistant [13,14]. These ¢ndings ful¢l the criteria estab-
lished for detection of Ap5A [13,14], suggesting that the myo-
cardium contains this member of the ApnA family.
The estimated level of Ap5A found in the normoxic myo-
cardium was 7.0 þ 0.6 WM (n = 6, Fig. 2B, open bar). In this
regard, the myocardium apparently possesses levels of Ap5A
higher than those previously found in the pancreas or liver
[21,22], but lower than levels found in secretory tissues such as
the adrenal medulla or platelets [13,23].
Little is known regarding the regulation of tissue levels of
Ap5A. After mechanical injury or a challenge with a nutrient,
tissue levels of certain ApnA, in particular diadenosine tri-
phosphate and diadenosine tetraphosphate, rise from nano-
molar to micromolar levels [21,22]. Here, in the heart, we
found that global 10-min ischemia, which is known to pro-
duce moderate metabolic stress [12], produced a signi¢cant
decrease in ventricular Ap5A which dropped from micro- to
submicromolar levels (P6 0.001; Fig. 2A and B).
The signi¢cance of ischemia-induced decrease in cardiac
Ap5A levels is at present unknown. Previously, in rapidly
dividing cells, stress-regulated dynamics of other ApnA have
been associated with regulation of proteins with nucleotide
binding domains involved in cellular signaling coupled to
DNA replication, growth and cell division [2,3,5^9,24]. How-
ever, the adult myocardium is a terminally di¡erentiated tis-
sue, for which the role of intracellular Ap5A remains to be
determined.
In cardiac cells, a major sensor of metabolic stress is the
ATP-sensitive K (KATP) channel, an ATP-gated ion conduc-
tance which opening promotes cellular survival under ische-
mic injury [25^28]. The nucleotide binding domains of the
KATP channel protein complex may serve as targets for
Ap5A [29^35]. We and others have previously shown that
moderate metabolic stress, including a 10-min long ischemia,
increases the probability of opening of cardiac KATP channels
[25^28,36]. In principle, a ligand of KATP channels which £uc-
tuate around its EC50, during ischemia, would profoundly
a¡ect channel opening under this condition. So far, no single
endogenous KATP channel ligand with such property has been
identi¢ed [25^28,31,37]. Ap5A antagonized the opening of
cardiac KATP channels, in excised membrane patches, with
an EC50 of 12.6 þ 1.7 WM (n = 6), a value close to the levels
of Ap5A found in the myocardium (Fig. 3A). Concentrations
of Ap5A, found in hearts prior to metabolic stress (range:
5.41 to 9.17 WM), maintained a low probability of KATP chan-
nel opening (Fig. 3B, C). Concentrations of Ap5A found in
hearts following global ischemia (range: 0.13 to 0.79 WM)
were associated with a high probability of channel opening
(Fig. 3B, C). Thus, Ap5A £uctuates during ischemic stress
within a range of concentrations which closely correspond
to the EC50 that de¢nes the action of this ApnA on the prob-
ability of KATP channel opening. Such property distinguishes
Ap5A from ATP, which also regulates the probability of
KATP channel opening, but which concentrations far exceed
the EC50 value for channel inhibition, regardless of the meta-
bolic state of the myocardium [25^28,31,37,38]. Therefore,
Ap5A should be considered as a potential, ischemia-sensing,
regulator of cardiac KATP channels.
In summary, the present study has identi¢ed Ap5A in the
myocardium, determined the regulation of Ap5A levels by
ischemic stress, and provided evidence for ischemia-dependent
regulation of KATP channels by Ap5A. Taken together, the
present data suggest that Ap5A harbors the properties of a
signaling molecule in the heart which may transduce the e¡ect
of ischemia on the activity of a metabolism-sensitive ion con-
ductance.
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